MedTrace Logo

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

NCT03127020 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-06-28

No results posted yet for this study

Summary

The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of PQR309 administered orally, as once daily capsules continuously and on intermittent schedule, in patients with relapsed or refractory lymphomas.

Conditions

Interventions

DRUG

PQR309

taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • University Hospital Munich

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • Charite University, Berlin, Germany

    collaborator OTHER

  • University of Stuttgart

    collaborator OTHER

  • PIQUR Therapeutics AG

    lead INDUSTRY

Principal Investigators

  • Martin Dreyling · Klinik Universität München

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-03-21

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03127020 on ClinicalTrials.gov